AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00993642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat (LBH589)
Description: Patients will be given five 30mg doses of HDAC inhibitor (LBH) over a period of two weeks. A dose will be taken on Days 1,3,5,8 and 10. Patients will have a diagnostic tumor biopsy prior to drug administration and a diagnostic biopsy within 48 hours (2 days) of the last dose.
Study NCT00761306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine (Lu AA21004)
Description: 5 or 10 mg/day; tablets; orally
Study NCT01524198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: 500 mcg budesonide plus Albuterol plus ipratropium bromide (IB) nebulization, 3 doses back to back
Study NCT01524198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 0.5 ml to 1.5 ml normal saline (to complete 3 mls total volume), plus albuterol plus ipratropium bromide nebulizations 3 doses back to back
Study NCT02142738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab IV solution
Study NCT02142738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel IV solution
Study NCT02142738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin IV solution
Study NCT02142738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed Lyophilized Powder for Infusion
Study NCT02142738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin IV solution
Study NCT02142738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine Lyophilized Powder for Infusion
Study NCT04737408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40mg
Description: Rosuvastatin 40 mg
Study NCT04737408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 40mg
Description: Rosuvastatin 40 mg
Study NCT00356083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Study NCT02742597 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TIP / IMPACT Plus Care Coordination
Description: The intervention will involve the patient attending an interdisciplinary team meeting, either through the Ontario Telemedicine Network's teleconferencing technology or in person, along with their caregiver(s), the referring practitioner, inter-professional (IP) teams and home care coordinators to discuss and uncover the patient's condition covering a diverse range of medical, functional and psycho-social issues and the development of a patient-centred treatment plan. The care plans are documented, shared, implemented and monitored by an assigned nurse from the program.
Study NCT01094587 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastroschisis closure with suture
Study NCT01094587 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastroschisis closure without suture
Study NCT03540225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Utrogestan Vaginal 200 mg or 400 mg daily from 11-14 Week or 20-24 Week until 34 Week
Study NCT02524522 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: INTELLiVENT-ASV mode
Description: Discontinuation with INTELLiVENT-ASV mode: discontinuation from mechanical ventilation in the early postoperative period will be provided by quick-wean option of INTELLiVENT-ASV mode
Study NCT02524522 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SIMV mode
Description: Discontinuation with SIMV mode: discontinuation with SIMV mode: discontinuation from mechanical ventilation in the early postoperative period will be provided in SIMV mode using physician driven algorithm
Study NCT04296877 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Daily Disposable Contact Lens
Description: Soft, daily disposable spherical contact lens used to correct distance vision.
Study NCT02005991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212377
Description: Single, oral dose administration of 70 mg PF-0521377 using a capsule formulation.
Study NCT02005991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212377
Description: Single, oral dose administration of 20 mg PF-0521377 using a capsule formulation. This dose is an estimate. The exact dose for Arm 2 will be based on the results from Arm 1.
Study NCT02005991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212377
Description: Single, oral dose administration of 10 mg PF-0521377 using a capsule formulation. This dose is an estimate. The exact dose for Arm 2 will be based on the results from Arms 1 and 2.
Study NCT03361150 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIT
Description: Both exercise protocol will be personalized, 3 times per week, 40-min exercise. HIT alternates a series of high-intensity bouts with relief period. MCT is continuous exercise with a constant intensity below anaerobic threshold.
Study NCT03361150 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MCT
Description: Both exercise protocol will be personalized, 3 times per week, 40-min exercise. MCT is continuous exercise with a constant intensity below anaerobic threshold.
Study NCT04002037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide 40mg/mL
Description: Corticosteroid injection will occur up to two times if trigger finger symptoms are not resolved.
Study NCT04002037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide 10mg/mL
Description: Corticosteroid injection will occur up to two times if trigger finger symptoms are not resolved.
Study NCT04002037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4 mg/ml
Description: Corticosteroid injection will occur up to two times if trigger finger symptoms are not resolved.
Study NCT03921320 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral sequential sympathectomy
Description: Bilateral videothoracoscopic sequential R4 sympathectomy
Study NCT03921320 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unilateral sympathectomy
Description: Unilateral videothoracoscopic R4 sympathectomy in dominant side (right side)
Study NCT03921320 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contralateral sympathectomy
Description: Contralateral (left side) videothoracoscopic R4 sympathectomy
Study NCT04183816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Total cold-water immersion
Description: TCWI group completed a session of 15-minutes in cold water with a temperature of 12°C.
Study NCT04183816 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ice massage
Description: Ice cubes massage in a clockwise circular motion on the thigh area (quadriceps) for 15 minutes.
Study NCT02408705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: They are receiving liraglutide for 3 months. Dose escalation: 0.3 mg - 0.6mg - 0.9mg - 1.2mg (over 4 weeks)
Study NCT02408705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: They are receiving placebo for 3 months. Dose escalation: 0.3 mg - 0.6mg - 0.9mg - 1.2mg (over 4 weeks)
Study NCT02408705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mixed Meal Tolerance Test with paracetamol
Description: At the beginning and end of each period (Visit 2a, 8, 9a, 15) a Mixed Meal Tolerance Test enriched paracetamol will be performed.
Study NCT02408705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mixed Meal Tolerance Test with paracetamol
Description: At the beginning and end of each period (Visit 2a, 8, 9a, 15) a Mixed Meal Tolerance Test enriched paracetamol will be performed.
Study NCT00750698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Entinostat (10 milligrams \[mg\] fixed dose orally \[PO\] every 2 weeks \[Q2W\]) on Days 1 and 15 of a 28-day cycle for up to 6 cycles
Study NCT00750698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib (150 mg PO QD) for up to six (6) 28-day cycles
Study NCT04144270 — intervention group
Intervention type: OTHER
Intervention: Evaluation of muscle mass and muscle function
Description: Included patients have their muscle mass and muscle function evaluated before start on and after completion of oncological treatment.
Study NCT03040791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab
Study NCT01434420 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BRCA1 BRCA2 PTEN PALB2 mutation
Description: detection of BRCA1 BRCA2 PTEN PALB2 mutation
Study NCT04467944 — intervention group
Intervention type: OTHER
Intervention: Pre-existing degenerative factors at adjacent segment
Description: Pre-existing degenerative factors at adjacent segment, including disc factors and canal stenosis factors
Study NCT00542464 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Imprime PGG TM for Injection
Description: Doses of 1.0 mg/kg-4.0 mg/kg of Imprime PGG administered over 1-2 hr for 7 consecutive days
Study NCT02071212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Loading dose 180 mg . Maintainance dose 90 mg BID
Study NCT02071212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Loading dose 180 mg . Maintainance dose 90 mg BID
Study NCT00710879 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bausch & Lomb Multi-Purpose Solution
Description: Daily care for contact lenses.
Study NCT01519804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching onartuzumab (MetMAb) placebo iv, Day 1 of each 21-day cycle
Study NCT01519804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin/carboplatin
Description: standard dose iv, Day 1 of each 21-day cycle, 4 cycles
Study NCT01519804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin/carboplatin
Description: standard dose iv, Day 1 of each 21-day cycle, 4 cycles
Study NCT01519804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onartuzumab
Description: 15 mg/kg iv, Day 1 of each 21-day cycle
Study NCT01519804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 200 mg/m2 iv, Day 1 of each 21-day cycle, 4 cycles
Study NCT01519804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 200 mg/m2 iv, Day 1 of each 21-day cycle, 4 cycles
Study NCT03621865 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TG
Description: Turmipure GOLD™ 30% curcuminoids (300 mg)
Study NCT03621865 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: STE
Description: Standard turmeric powder extract 95% curcuminoids (1500 mg)
Study NCT03621865 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NOV
Description: Novasol® Liquid micellar formulation 6% curcuminoids (1000 mg)
Study NCT03621865 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PHYT
Description: Meriva® Turmeric Phytosome formulation 20% curcuminoids (1000 mg)
Study NCT03621865 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TEP
Description: Turmeric extract C3 complex® 95% curcuminoids (1500mg) + BioPerine® 95% piperine (15 mg)
Study NCT03143010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intrathecal Dexmedetomidine
Description: injection of different doses of Dexmedetomidine intrathecally received 3mL (15mg) of 0.5% levobupivacaine +0.5mL normal saline.
Study NCT03143010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.5 micrograms
Description: injection of different doses of Dexmedetomidine intrathecally in the form of 3mL (15mg) of 0.5% levobupivacaine +0.5mLof 1.5 micrograms of Dexmedetomidine.
Study NCT03143010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 3 micrograms
Description: injection of different doses of Dexmedetomidine intrathecally in the form of 3mL (15mg) of 0.5% levobupivacaine +0.5mLof 3 micrograms of Dexmedetomidine.
Study NCT03143010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 5 micrograms
Description: injection of different doses of Dexmedetomidine intrathecally in the form of 3mL (15mg) of 0.5% levobupivacaine +0.5mLof 5 micrograms of Dexmedetomidine.
Study NCT03887533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTS-270
Description: Intravenous VTS-270 was administered on a monthly dosing schedule for 12 months. Each participant received one of two doses (500 or 1000mg/kg). Participants also received monthly 900 mg intrathecal VTS-270 therapy.
Study NCT03378804 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Programmed intermittent epidural bolus application (PIEB)
Description: Instead of a continuous background infusion of 6ml/h, one bolus injection is performed at the same amount per hour.
Study NCT03378804 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continous epidural analgesia
Study NCT02430142 — intervention group
Intervention type: OTHER
Intervention: Vasoocclusive testing
Description: Forearm vasoocclusive testing with a laser-doppler spectrophotometry system, transpulmonary thermodilution and blood sampling;
Study NCT01841502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: paroxetine 20 mg once daily
Study NCT01841502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: paroxetine 20 mg once daily
Study NCT01841502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir
Description: telaprevir 1125 mg twice daily
Study NCT04106882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketones
Description: Supplement administered mid-scan.
Study NCT04106882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Supplement administered mid-scan.
Study NCT06397755 — intervention group
Intervention type: PROCEDURE
Intervention: Prostate Biopsy and/or Radical Prostatectomy
Description: Prostate Biopsy: procedure to remove samples of suspicious tissue from the prostate Radical Prostatectomy: surgery to remove the prostate gland and seminal vesicles (and sometimes nearby lymph nodes) after a prostate cancer diagnosis
Study NCT04368572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: An interview assesses the patient's level of anxiety, interests and dissociative abilities. Hypnosis is done by following the steps:~First step: reception and installation of the patient Second step: induction phase Third step: hypnotic trance phase Fourth step: reorientation phase
Study NCT04368572 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hypnosis
Description: An interview assesses the patient's level of anxiety, interests and dissociative abilities. Hypnosis is done by following the steps:~First step: reception and installation of the patient Second step: induction phase Third step: hypnotic trance phase Fourth step: reorientation phase
Study NCT01858532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atrasentan
Description: Film-coated tablet
Study NCT01858532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablet
Study NCT02080442 — intervention group
Intervention type: OTHER
Intervention: Balance training
Description: Training will consist of 30 minute sessions 2-3 times/week for a total of 18-24 sessions, in keeping with best practice guidelines for older adults.12 Sessions will be supervised by physical therapists, using a circuit training approach with different stations designed to target specific areas of impairment. Participants will work through stations in a group setting; however, will receive individualized exercise prescription regarding level of difficulty and exercise progression.
Study NCT04308070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AQUABEAM System followed by catheter without hemostatic agent
Description: The AquaBeam system delivers a high-pressure saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The physician will use balloon catheter to achieve hemostasis post-Aquablation procedure.
Study NCT04308070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AQUABEAM System followed by catheter with hemostatic agent
Description: The AquaBeam system delivers a high-pressure saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The physician will use balloon catheter with hemostatic agent to achieve hemostasis post-Aquablation procedure.
Study NCT02593162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faldaprevir
Study NCT02593162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-6450
Study NCT02593162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Study NCT02407262 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Black seed oil
Study NCT02407262 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: vegetable oil
Study NCT03537144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: IV indomethacin will be given every 12 hours for 3 doses. If \<48 hours old, 1st dose 0.2 mg/kg, 2nd dose 0.1 mg/kg, and 3rd dose 0.1mg/kg. If 2-7 days old, 1st dose 0.2 mg/kg, 2nd dose 0.2 mg/kg, and 3rd dose 0.2 mg/kg. If >7 days old, 1st dose 0.2 mg/kg, 2nd dose 0.25 mg/kg, and 3rd dose 0.25 mg/kg.
Study NCT03537144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 15mg/kg/dose every 6 hours for 12 doses
Study NCT00012220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 50 mg/sq m IV infusion over 30 min on Days 1 \& 15 of ea cycle
Study NCT00012220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 40 mg/sq m IV infusion over 60 min on Days 1 \& 8 of ea treatment cycle
Study NCT00012220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride
Description: Gemcitabine only arm: 1500 mg/sq m in 250 mL NS IV infusion over 150 min Days 1, 8, \& 15 of ea cycle~* cisplastin arm: 1000 mg/sq m 250 mL NS IV infusion over 30 min Days 1, 8, 15 of ea cycle~* docetaxel and + irinotecan arms: 1000 mg/sq m in 250 mL NS IV infusion over 30 min Days 1 \& 8 of ea cycle
Study NCT00012220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Gemcitabine only arm: 1500 mg/sq m in 250 mL NS IV infusion over 150 min Days 1, 8, \& 15 of ea cycle~* cisplastin arm: 1000 mg/sq m 250 mL NS IV infusion over 30 min Days 1, 8, 15 of ea cycle~* docetaxel and + irinotecan arms: 1000 mg/sq m in 250 mL NS IV infusion over 30 min Days 1 \& 8 of ea cycle
Study NCT00012220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: 100 mg/q m in 500 mL D5W or D5NS IV infusion over 90 min Days 1 \& 8 of ea cycle
Study NCT03974776 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06946860
Description: PF-06946860 administered subcutaneously
Study NCT03974776 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously
Study NCT01554644 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prontosan
Description: Prontosan(TM) Wound Irrigation Solution (PHMB 0.1%, Betaine 0.1%) and Prontosan(TM) Wound Gel (PHMB 0.1%, Betaine 0.1%). Dressings will be changed and the treatment procedure will be repeated daily with 30ml/40 ml wound solution and 30 ml wound gel for a period of 12 weeks.
Study NCT01554644 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline Wound Irrigation Solution and inert Wound Gel. Dressings will be changed and the treatment procedure will be repeated daily with 30ml/40 ml wound solution and 30 ml wound gel for a period of 12 weeks.
Study NCT01888120 — intervention group
Intervention type: DRUG
Intervention: Ziconotide
Study NCT03778528 — intervention group
Intervention type: PROCEDURE
Intervention: cataract surgery
Description: tissue collection.
Study NCT00003440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV over 1 hour or 3 hours
Study NCT00003440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Given IV over 1 hour or 3 hours
Study NCT00003440 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV
Study NCT00003440 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Description: Given IV
Study NCT00003440 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT00003440 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies